Transcriptomic response of peripheral blood mononuclear cells to secukinumab in an 8‐year‐old boy with juvenile generalized pustular psoriasis

Infantile generalized pustular psoriasis with excellent response to secukinumab: A case report

“…[1][2][3] The loss-of-function mutation of interleukin-36 receptor antagonist (IL36Ra) has been associated with development of GPP. 4 Interestingly, IL-17 mRNA levels were also noted to be higher in pustular psoriasis in comparison with other clinical subtypes. 5 We reported a three-month-old Filipino girl born at term via caesarean section with otherwise unremarkable antenatal and birth history.…”

“…Secukinumab 75 mg was administered subcutaneously for three weekly doses based on the report of López-Sánchez et al 5 The authors also had previous experience of its use similar to other studies. 4,6,7 The patient (6.3 kg, GPPASI: 29.2, GPPGA: 4) demonstrated remarkable response one week after the first dose (GPPASI: 6, GPPGA: 2) and achieved clear skin one week after the third dose (GPPASI: 0, GPPGA: 0). There was no recurrence of lesions nor adverse events at 11-month follow-up.…”

“…In recent years, the pathogenesis of GPP has been explored between the interaction of the IL-36 axis and TNFα/IL-17/IL-22 axis. 4 Hence, targeting IL-17 plays an important role in the control of GPP. A recent study has shown good efficacy and safety of IL-17A antagonists in a young boy with GPP, which also showed rapid reduction in inflammatory pathways.…”

“…A recent study has shown good efficacy and safety of IL-17A antagonists in a young boy with GPP, which also showed rapid reduction in inflammatory pathways. 4 Furthermore, secukinumab was also successfully used in an infant with GPP who failed to respond to other medications. 6 Therefore, these prove the importance of targeting the IL-17 pathway for GPP.…”